請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40291
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙(Tony Hsiu-Hsi Chen) | |
dc.contributor.author | Ming-Jeng Kuo | en |
dc.contributor.author | 郭明正 | zh_TW |
dc.date.accessioned | 2021-06-14T16:44:10Z | - |
dc.date.available | 2009-09-11 | |
dc.date.copyright | 2008-09-11 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-30 | |
dc.identifier.citation | 1. Global Cancer Statistics, 2002
2. Chang MH, Chen CJ, Lai MS,Hsu HM,Wu TC,Kong MS,Liang DC,Shau WY,Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9 3. Donato F A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54. 4. Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004;38:S148-52. 5. Wun YT, Dickinson, J. A. Cochrane Database Syst Rev 2003:CD002799. 6. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-8. 7. El-Serag HB, Siegel AB, Davila JA,Shaib YH,Cayton-Woody M,McBride R,McGlynn KA. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006;44:158-66. Epub 2005 Nov 2. 8. Llovet JM Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38. 9. Llovet JM, Bruix J, Fuster J,Castells A,Garcia-Valdecasas JC,Grande L,Franca A. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998;27:1572-7. 10. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115-20. 11. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. 12. Lin CP, Yu HC, Cheng JS,Lai KH,Lo GH,Hsu PI,Lin CK,Chen HH,Lo CC,Liang HL,Tseng HH. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004;67:602-10. 13. 95年衛生統計 14. Jan CF, Chen CJ , Chen HH Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. J Gastroenterol Hepatol 2005 Apr;20(4):521-6 15. Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res 2007;37:S101-5. 16. Lee CM, Lu SN, Chang CS,Yeh CT, Hsu TT, Tang JH,Wang JH. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999;86:1143-50. 17. Ni YH, Chang MH, Huang LM,Chen HL,Hsu HY,Chiu TY,Tsai KS, DS C. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800. 18. Chen CH YP, Huang GT,Lee HS,Sung JL,Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148-55. 19. Liaw YF, Sung JJ, Chow WC,Farrell G,Lee CZ,Yuen H. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31 20. Lai CL ,Liaw YF, Hsu CW,Thongsawat S,Wang Y,Chen Y. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88. 21. Lai CL ,Lok AS,Chang TT,Cheinquer H,Goodman Z,DeHertogh D. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. 22. Hadziyannis SJ.Tassopoulos NC HE, Chang TT.Kitis G,Rizzetto M,Marcellin P,Lim SG. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81. 23. Yu ML, Lin SM, Chuang WL,Dai CY,Wang JH,Lu SN,Sheen IS,Chang WY,Lee CM,Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985-94. 24. Shiratori Y Shinna S, Imamura M,Kato N,Kanai F,Okudaira T, Teratani T, Tohgo G,Toda N,Ohashi M. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995;22:1027-33 25. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:E25-30. 26. Massard J Ratziu V, Thabut D,Moussalli J,Lebray P,Benhamou Y,Poynard T. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006;44:S19-24. Epub 2005 Nov 21. 27. Sheu JC,Sung JL, Chen DS,Yang PM,Lai MY,Lee CS,Hsu HC,Chuang CN,Yang PC,Wang TH et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259-66. 28. Pateron D,Ganne N, Trinchet JC,Aurousseau MH,Mal F,Meicler C,Coderc E,Reboullet P. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994;20:65-71. 29. Daniele B, Bencivenga A, Megna AS, et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108-12. 30. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008;14:1652-6. 31. Chen TH, Chiu YH, Luh DL, Yen MF,Wu HM,Chen LS,Tung TH,Huang CC,Chan CC,Shiu MN,Yeh YP,Liou HH,Liao CS,Lai HC,Chiang CP,Peng HL,Tseng CD,Yen MS,Hsu WC,Chen CH. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 2004;100:1734-43 32. Torzilli G MM, Takayama T,Inoue K,Hui AM,Kubota K,Ohtomo K,Makuuchi M. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999;30:889-93. 33. Morris Sherman, Kevork M. Peltenan, Cindy Lee Screening for Hepatocellular Carcinoma in Chronic Carriers of Hepatitis B Virus: Incidence and Prevalence of Hepatocellular Carcinoma in a North American Urban Population Hepatology Vol . 22, No. 2, 1995 34. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999;6:108-10. 35. Yang B , Zhang B, Tang Z, Randomized controlled prospective study of secondary prevention for primary liver cancer Zhonghua Yi Xue Za Zhi 1999;79:887-889 36. Mima S, Sekiya C, Kanagawa H, et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994;9:361-5. 37. Chen CJ, Lu SN, You SL,Wu MH,Wang LY,Lee LT,Huang GT,Yang PM,Lee HS, et al. [Community-based hepatocellular carcinoma screening in seven townships in Taiwan]. J Formos Med Assoc 1995;94:S94-102. 38. Chen TH, Chen CJ, Yen MF,Lu SN,Sun CA,Huang GT,Yang PM,Lee HS,Duffy SW. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002;98:257-61. 39. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422-34. 40. Yuen MF, Cheng CC, Lauder IJ,Lam SK,Ooi CG,Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5. 41. Bolondi L, Sofia S, Siringo S,Gaiani S,Casali A,Zironi G,Piscaglia F,Gramantieri L,Zanetti M,Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9. 42. Saab S, LyD, Nieto J, Kanwal F, D L, S R, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003;9:672-81. 43. Arguedas MR Chen VK, Eloubeidi MA,Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679-90. 44. Lin OS Keeffe EB, Sanders GD,Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004;19:1159-72. 45. Hsu C, Cheng JC, Cheng AL. Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. J Formos Med Assoc 2004;103:483-95 46. Wu GH, Boucher BJ, Chiu YH, Liao CS, Chen TH. Impact of chewing betel-nut (Areca catechu) on liver cirrhosis and hepatocellular carcinoma: a population-based study from an area with a high prevalence of hepatitis B and C infections. Public Health Nutr 2008:1-7. 47. Llovet JM, Bustamante J, Castells A,Vilana R,Ayuso Mdel C,Sala M,Bru C,Rodes J,Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7. 48. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56. 49. Liaw YF Lin DY, Chen TJ,Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9:235-41. 50. Fattovich G , Giustina G, Degos F,Tremolada F,Diodati G,Almasio P,Nevens F,Solinas A,Mura D,Brouwer JT,Thomas H, Njapoum C,Casarin C,Bonetti , et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72. 51. Serfaty L, A. H., Chazouilleres O,Bonnand AM,Rosmorduc O,Poupon RE,Poupon R (1998). 'Determinants of outcome of compensated hepatitis C virus-related cirrhosis.' Hepatology. 27(5): 1435-40. 52. Kuo MJ, Yeh HZ, Chen GH,Poon SK,Yang SS,Lien HC,Chang CS. Improvement of tissue-adhesive obliteration of bleeding gastric varices using adjuvant hypertonic glucose injection: a prospective randomized trial. Endoscopy 2007;39:487-91. Epub 2007 Mar 13. 53. Lin DY, Sheen IS,Chiu CT,Lin SM,Kuo YC,Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993;21:303-8. 54.肝癌患者罹病成本與其相關因子之探討:以某醫學中心患者為例。中華衛誌,17(2),148-157。吳季倫、楊銘欽(1998)。 55. Yu EW Chie WR, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J 2004;10:317-25. 56. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51. 57. Lu SN, Wang JH, Liu SL,Hung CH,Chen CH,Tung HD,Chen TM,Huang WS,Lee CM,Chen CC,Changchien CS. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006;107:2212-22. 58. Taplin SH, Barlow W, Urban N,Mandelson MT,Timlin DJ,Ichikawa L,Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-26. 59.肝癌患者醫療成本分析 : 以某醫學中心患者為例 楊少萱、湯澡薰、洪維河 2003 (台北醫學大學醫務管理學硏究所碩士論文) 60. Tabar L , Fagerberg CJ, Gad A,Baldetorp L,Holmberg LH,Grontoft O,Ljungquist U,Lundstrom B,Manson JC,Eklund G,et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-32. 61.Yu MW, Chen PJ,Liaw YF,Lin CL,Liu CJ,Shih WL,Kao JH,Chen DS,Chen CJ (2005). 'Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.' J Natl Cancer Inst. 97(4): 265-72. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40291 | - |
dc.description.abstract | 在台灣肝癌是最常見的惡性腫瘤之一,並且是癌症致死率排名的首位。由於早期肝癌的症狀並不明顯,肝癌在臨床上往往在中、晚期才被診斷出來,可接受根治性治療的比率不高; 因此篩檢出早期肝癌是十分重要的。已有不少研究證實以超音波為基礎的肝癌篩檢策略可提升無症狀的小型肝癌的發現率及手術的可切除率,甚至延長患者的存活,但不同篩檢策略的成本效果如何,目前仍待釐清。
我們使用馬可夫決策分析模式,針對B 型肝炎高盛行地區的一般40歲以上社區民眾的假設世代,比較三種不同肝癌篩檢策略,包括(1)完全沒有篩檢的介入(2)以二階段篩檢為基礎的肝癌篩檢(3) 大規模的腹部超音波肝癌篩檢。我們根據過去社區肝癌篩檢的經驗,以電腦模擬肝癌的自然史,並建立不同肝癌篩檢策略的決策樹模型,以進行成本效果分析。篩檢參數的取得主要來自本土肝癌篩檢及大型世代研究的整合分析。在考量成本效果分析中的參數有其不確定性,我們使用單向敏感度分析的方法將參數值在合理範圍內調整;也使用機率性敏度分析方法將參數間的不確定性予以結合。另外,我們也嘗試比較不同的篩檢起始點及不同的篩檢間隔的成本效益。 研究結果顯示,我們的模型對肝癌死亡率的預測和國內肝癌死亡資料相比較並無差異。和沒接受篩檢比較起來,每增加一個人年的成本在大規模的腹部超音波篩檢為新台幣1874433元,在二階段的篩檢則為新台幣2164578元。大規模的腹部超音波篩檢比起二階段篩檢平均每人可多獲得0.0014年的平均餘命且只要多付出約新台幣216元的篩檢成本,因此較符合成本效果。若願意付出的上限值定在新台幣566,566元(相當於96年的台灣平均國民生產毛額),則肝癌的篩檢策略並不符合成本效果。敏感度分析的結果,肝癌治療的存活率及肝硬化的盛行率是決定次段預防是否具成本效果的決定因子。而篩檢工具的價格及生化值篩檢的特異度是決定不同篩檢策略相對成本效果的重要因子。此外,兩年一次的篩檢間隔及50歲開始的篩檢年齡比起基礎值分析所用的40歲篩檢起始點及每年的篩檢間隔具成本效果 本研究的結論為: 社區大規模腹部超音波篩檢比二階段肝癌篩檢具成本效果,篩檢工具的價格及生化值篩檢的特異度決定相對的成本效果。50歲開始的篩檢年齡及兩年一次的篩檢間隔具最佳的篩檢成本效果。 關鍵詞: 肝癌, 二階段篩檢, 大規模腹部超音波篩檢, 馬可夫模式, 成本效果, 敏感度分析 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma (HCC) is one of the most common cancers and is the leading cause of cancer death in Taiwan. Hepatocellular carcinoma in early stage is usually asymptomatic and patients commonly manifest with advanced diseases. Curative surgery is only feasible for a few patients and it’s extremely important to make early diagnosis of HCC. Ultrasonography (US) is widely believed to be an effective form of secondary prevention for HCC and many studies showed its efficacy to increase the detecting rate of small tumor and increase the proportion of curative treatment . However there is a lack of empirical evidence showing the cost-effectiveness of US screening .
A Markov model was used to estimate the expected lifetime costs and outcomes associated with screening strategies for HCC in a hypothetical cohort of 40-yr-old community residents. We compared the following strategies for HCC screening: No screening, two-stage screening and mass screening with US. Parameters of natural history , sensitivity and specificity of biochemical screenig were derived from our previous studies of two-stage liver cancer screening. Accuracy of ultrasonograpy screening , mortality associated with the specific stage of liver were based on meta-analysis. Deterministic and probabilistic sensitivity analysis were performed to assess the effects of uncertainty of parameters. We also evaluate the relative costs and effectiveness by comparing different screening strategies with different inter-screening interval and initial age. Mass screening with ultrasonography was associated with an incremental cost-effectiveness ratio of NT $1,874,433 per life-year gained whereas two-stage screening was associated with an incremental cost-effectiveness ratio of NT $ 2,164,578 per life-year gained compared with no screening .Mass screening with ultrasongoraphy seems cost-effective than two-stage screening. The screening programs intiated at the age of 50 years and with biennial screning interval have a better cost-effevtiveness ratio. In conclusion mass screening with ultrasonography, particularly intiated form 50 years of age with two inter-screening interval, is more cost-effective than two-stage screening . The relative cost-effectiveness may vary with costs of screening tools and the specificity of biochemical screening. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T16:44:10Z (GMT). No. of bitstreams: 1 ntu-97-R95846015-1.pdf: 542917 bytes, checksum: 9d3794e4c07e6ef7f3c4cc5c97d8c5b9 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 內容索引
誌 謝………………………………………………………………………………I 中文摘要………………………………………………………………………………III 英文摘要………………………………………………………………………………V 內容索引…………………………………………………………………………… VII 表格目錄………………………………………………………………………………X 圖目錄 ……………………………………………………………………………… XI 第一章 肝癌之現況……………………………………………………………… 1 1.1肝癌的流行病學………………………………………………………………… 1 1.2肝癌的危險因子………………………………………………………………… 2 1.3肝癌的初段及次段預防………………………………………………………… 3 1.4肝癌的治療……………………………………………………………………… 4 1.5台灣的肝癌現況………………………………………………………………… 5 1.6 研究假說………………………………………………………………………… 7 第二章 肝癌之篩檢及相關文獻回顧………………………………………………9 2.1肝癌的自然病史………………………………………………………………… 9 2.2肝癌的篩檢……………………………………………………………………… 11 2.3社區型肝癌篩檢策略…………………………………………………………… 13 2.4肝癌篩檢的成本效果…………………………………………………………… 16 第三章 研究方法及材料…………………………………………………………… 24 3.1 目標族群 …………………………………………………………………… 24 3.2 篩檢策略…………………………………………………………………… 24 3.3 肝癌自然史的量化………………………………………………………… 25 3.4 決策分析的模型架構……………………………………………………… 27 3.5 模型的假設………………………………………………………………… 30 3.6 篩檢的重要參數…………………………………………………………… 31 3.7 篩檢參數的整合分析方法 ………………………………………………… 32 3.8 模式驗証 …………………………………………………………………… 34 3.9 成本效果分析 ……………………………………………………………… 34 3.10 敏感度分析 ………………………………………………………………… 34 第四章 研究結果 ………………………………………………………………… 36 4.1 基礎值的估計 ……………………………………………………………… 36 4.2 成本的估計 ………………………………………………………………….36 4.3 敏感度分析及闕值 ………………………………………………………… 38 4.4 篩檢起始年齡的分析 ……………………………………………………… 38 4.5 篩檢間隔的比較 …………………………………………………………… 39 4.6 可接受度曲線分析 ………………………………………………………… 41 4.7 模式驗証 …………………………………………………………………… 44 第五章 討論 ………………………………………………………………………52 5.1 研究主要發現 ……………………………………………………………… 52 5.2 肝癌次段預防成本效果的重要決定因子 ………………………………… 52 5.3 大規模腹部超音波篩檢比二階段篩檢更具成本效果的原因探討 …………53 5.4 直接成本及間接成本 ……………………………………………………… 54 5.5 篩檢間隔及起始年齡 ……………………………………………………… 54 5.6 和過去肝癌成本效果研究的比較 ………………………………………… 55 5.7 研究的優點與限制 ……………………………………………………………55 第六章 結論………………………………………………………………………… 57 English Manuscript……………………………………………………………………58 論文索引 ……………………………………………………………………………68 表格目錄 表1-1 腹部超音波在肝癌篩檢準確性的文獻回顧 ……………………………… 8 表 2-1 血清胎兒蛋白在肝癌篩檢的敏感度、特異度、陽性預期值以及陰性預期值的文獻回顧……………………………………………………………………19 表2-2 社區型肝癌篩檢的文獻回顧…………………………………………………20 表2-3 肝癌篩檢成本效果的文獻回顧………………………………………………22 表4-1 年度死於及存活的肝癌患者的醫療花費……………………………………37 表4-2 肝癌治療的初始治療費用及持續治療費用…………………………………37 表4-3比較臨床個案的疾病嚴重度之平均住院日數、平均醫療費用( 包含門診及住 院的平均醫療費用)及平均追蹤時間 ………………………………………………38 表4-4不同起始年齡的篩檢策略和無篩檢介入比較的增加成本效果比…………39 表4-5 不同時間間隔的篩檢策略和無篩檢介入比較的增加成本效果比…………41 表4-6模擬肝癌自然病史之基礎值及敏感度分析的範圍………………………….45 表4-7 以最佳估計值估計不同肝癌篩檢策略的增加成本效果比…………………49 表4-8 單方向敏感度分析……………………………………………………………50 圖目錄 圖3-1 為二階段肝癌篩檢流程圖圖示………………………………………………25 圖3-2 肝癌自然史的馬可夫模式之圖示……………………………………………26 圖 3-3 四階段馬可夫模式轉移機率的矩陣圖形……………………………………27 圖3-4 比較不同篩檢策略的決策樹模型…………………………………………… 28 圖3-5(a) 非肝硬化的疾病自然史模型………………………………………………28 圖3-5(b) 肝硬化的疾病自然史模型…………………………………………………28 圖3-5(c) 臨床前期的肝癌的疾病自然史模型………………………………………28 圖3-5(d) 有症狀肝癌的疾病自然史模型……………………………………………28 圖3-6(a) 二階段篩檢對肝硬化非肝癌患者的決策模型……………………………29 圖3-6(b) 大規模的腹部超音波篩檢對臨床前期肝癌患者的決策模型……………29 圖3-7(a) 篩檢結果為肝硬化的決策模型……………………………………………29 圖3-7(b) 篩檢結果為肝癌患者的決策模型…………………………………………30 圖 3-8 肝癌發生率的年齡別圖示……………………………………………………31 圖3-9 為腹部超音波對肝癌篩檢敏感度及精確度的整合分析示意圖…………… 33 圖3-10 為肝硬化死亡率的整合分析示圖 ………………………………………… 33 圖4-1 篩檢策略在不同篩檢起始年齡的增加成本效果的比較圖示……………… 39 圖4-2顯示不同篩檢策略在不同篩檢間隔的成本效果分佈 ………………………40 圖4-3 (a)不同篩檢策略在最佳估計值下的可接受度曲線的分佈 …………………41 圖4-3(b)比較一年間期的三種不同篩檢策略的可接受度曲線的分佈(生化值篩檢的成本為新台幣400元)…………………………………………………………………42 圖4-4(a)二階段篩檢和無篩檢比較的增加成本效果散布圖……………………… 43 圖4-4(b)大規模的腹部超音波篩檢和無篩檢比較的增加成本效果散布圖……… 43 圖4-4(c)大規模的腹部超音波篩檢和二階段篩檢比較的增加成本效果散布圖… 43 圖4-5 篩檢策略在不同篩檢間隔的可接受度曲線分析 ……………………………44 | |
dc.language.iso | zh-TW | |
dc.title | 社區肝癌篩檢的成本效果分析--比較腹部超音波篩檢及二階段篩檢 | zh_TW |
dc.title | Cost-Effectiveness of Population-Based Hepatocellular
Carcinoma Screening -- Comparison between Ultrasonography Screening and Two-stage Screening | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 嚴明芳 | |
dc.contributor.oralexamcommittee | 張淑惠,楊銘欽,廖朝聖 | |
dc.subject.keyword | 肝癌,二階段篩檢,大規模腹部超音波篩檢,馬可夫模式,成本效果,敏感度分析, | zh_TW |
dc.subject.keyword | hepatocellular carcinoma,two-stage screening,mass screening with ultrasonography,Markov model,cost-effectiveness,sensitivity analysis, | en |
dc.relation.page | 74 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-08-01 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 530.19 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。